Advanced search
1 file | 156.82 KB Add to list

HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens

Author
Organization
Abstract
Objectives: Whether ART regimens differ in their propensity to allow persistent HIV-1 detection remains unclear. To investigate this, we performed a cross-sectional study to characterize HIV-1 persistence in peripheral blood during suppressive therapy with NRTIs plus a PI or nevirapine. Methods: Residual plasma HIV-1 RNA was quantified by real-time PCR. Cell-associated proviral total HIV-1 DNA, unspliced and multiply spliced HIV-1 RNA and 2-long terminal repeat (2-LTR) circles were quantified by digital PCR. Results: Comparing PI with nevirapine recipients, residual plasma HIV-1 RNA detection rates were 47/80 (58.8%) versus 37/81 (45.7%), with median (IQR) levels of 4 (3–8) versus 4 (3–7) copies/mL (P = 0.207); detection was less likely with longer duration of suppressive ART (P = 0.020), independently of treatment. HIV-1 DNA was detected in all patients, with median levels of 2.3 (IQR 2.0–2.7) versus 2.5 (IQR 2.1–2.7) log10 copies/106 PBMCs, respectively; HIV-1 DNA levels were associated with pre-ART viral load (P = 0.004) and with residual HIV-1 RNA (P = 0.034), unspliced HIV-1 RNA (P = 0.001) and 2-LTR circles (P = 0.005), independently of treatment. Conclusions: No significant differences were revealed in levels of residual plasma HIV-1 RNA, total HIV-1 DNA or intracellular markers of ongoing virus replication (unspliced and multiply spliced HIV-1 RNA and 2-LTR circles) between treatment groups.
Keywords
ULTRASENSITIVE ASSESSMENT, LOW-LEVEL VIREMIA, RESIDUAL VIREMIA, PLASMA, INFECTION, COPIES/ML, RESERVOIR, RISK, HAART-TREATED PATIENTS, ACTIVE ANTIRETROVIRAL THERAPY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 156.82 KB

Citation

Please use this url to cite or link to this publication:

MLA
Kiselinova, Maja et al. “HIV-1 RNA and HIV-1 DNA Persistence During Suppressive ART with PI-based or Nevirapine-based Regimens.” JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 70.12 (2015): 3311–3316. Print.
APA
Kiselinova, M., Geretti, A. M., Malatinková, E., VERVISCH, K., Beloukas, A., Messiaen, P., Bonczkowski, P., et al. (2015). HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3311–3316.
Chicago author-date
Kiselinova, Maja, Anna Maria Geretti, Eva Malatinková, KAREN VERVISCH, Apostolos Beloukas, Peter Messiaen, Pawel Bonczkowski, et al. 2015. “HIV-1 RNA and HIV-1 DNA Persistence During Suppressive ART with PI-based or Nevirapine-based Regimens.” Journal of Antimicrobial Chemotherapy 70 (12): 3311–3316.
Chicago author-date (all authors)
Kiselinova, Maja, Anna Maria Geretti, Eva Malatinková, KAREN VERVISCH, Apostolos Beloukas, Peter Messiaen, Pawel Bonczkowski, Wim Trypsteen, Steven Callens, Chris Verhofstede, Ward De Spiegelaere, and Linos Vandekerckhove. 2015. “HIV-1 RNA and HIV-1 DNA Persistence During Suppressive ART with PI-based or Nevirapine-based Regimens.” Journal of Antimicrobial Chemotherapy 70 (12): 3311–3316.
Vancouver
1.
Kiselinova M, Geretti AM, Malatinková E, VERVISCH K, Beloukas A, Messiaen P, et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015;70(12):3311–6.
IEEE
[1]
M. Kiselinova et al., “HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens,” JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 70, no. 12, pp. 3311–3316, 2015.
@article{6956517,
  abstract     = {Objectives: Whether ART regimens differ in their propensity to allow persistent HIV-1 detection remains unclear. To investigate this, we performed a cross-sectional study to characterize HIV-1 persistence in peripheral blood during suppressive therapy with NRTIs plus a PI or nevirapine.
Methods: Residual plasma HIV-1 RNA was quantified by real-time PCR. Cell-associated proviral total HIV-1 DNA, unspliced and multiply spliced HIV-1 RNA and 2-long terminal repeat (2-LTR) circles were quantified by digital PCR.
Results: Comparing PI with nevirapine recipients, residual plasma HIV-1 RNA detection rates were 47/80 (58.8%) versus 37/81 (45.7%), with median (IQR) levels of 4 (3–8) versus 4 (3–7) copies/mL (P = 0.207); detection was less likely with longer duration of suppressive ART (P = 0.020), independently of treatment. HIV-1 DNA was detected in all patients, with median levels of 2.3 (IQR 2.0–2.7) versus 2.5 (IQR 2.1–2.7) log10 copies/106 PBMCs, respectively; HIV-1 DNA levels were associated with pre-ART viral load (P = 0.004) and with residual HIV-1 RNA (P = 0.034), unspliced HIV-1 RNA (P = 0.001) and 2-LTR circles (P = 0.005), independently of treatment.
Conclusions: No significant differences were revealed in levels of residual plasma HIV-1 RNA, total HIV-1 DNA or intracellular markers of ongoing virus replication (unspliced and multiply spliced HIV-1 RNA and 2-LTR circles) between treatment groups.},
  author       = {Kiselinova, Maja and Geretti, Anna Maria and Malatinková, Eva and VERVISCH, KAREN and Beloukas, Apostolos and Messiaen, Peter and Bonczkowski, Pawel and Trypsteen, Wim and Callens, Steven and Verhofstede, Chris and De Spiegelaere, Ward and Vandekerckhove, Linos},
  issn         = {0305-7453},
  journal      = {JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY},
  keywords     = {ULTRASENSITIVE ASSESSMENT,LOW-LEVEL VIREMIA,RESIDUAL VIREMIA,PLASMA,INFECTION,COPIES/ML,RESERVOIR,RISK,HAART-TREATED PATIENTS,ACTIVE ANTIRETROVIRAL THERAPY},
  language     = {eng},
  number       = {12},
  pages        = {3311--3316},
  title        = {HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens},
  url          = {http://dx.doi.org/10.1093/jac/dkv250},
  volume       = {70},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: